Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420270 | 0.85 | MAOB (0.52) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL690501 | 0.82 | KAT6A (0.54) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL496275 | 0.81 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL29459930 | 0.81 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL28208860 | 0.81 | KAT6A (0.52) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10561497 | 0.81 | KAT6A (0.52) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6748367 | 0.80 | KAT6A (0.55) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2095288 | 0.79 | KAT6A (0.51) | MAOBKAT6ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29448761 | 0.79 | PARP1 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MAPK1 | |
| SCHEMBL711132 | 0.79 | PARP1 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | MAOB 483/4885KAT6A 1019/4885TAS1R3 566/4885 |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | MAOB 743/4885KAT6A 434/4885TAS1R3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.